At the time of writing, OnKure Therapeutics Inc [OKUR] stock is trading at $2.32, up 5.45%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The OKUR shares have gain 26.09% over the last week, with a monthly amount drifted -15.02%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Leerink Partners started tracking the stock with Outperform rating on December 05, 2024, and set its price target to $33. On October 10, 2024, Oppenheimer initiated with a Outperform rating and assigned a price target of $35 on the stock. Leerink Partners downgraded its rating to a Market Perform. Jefferies downgraded its rating to a Hold. H.C. Wainwright downgraded its rating to Neutral for this stock on December 15, 2023, and downed its price target to $1.50. In a note dated December 14, 2023, William Blair downgraded an Mkt Perform rating on this stock.
For the past year, the stock price of OnKure Therapeutics Inc fluctuated between $1.70 and $20.00. Currently, Wall Street analysts expect the stock to reach $35 within the next 12 months. OnKure Therapeutics Inc [NASDAQ: OKUR] shares were valued at $2.32 at the most recent close of the market. An investor can expect a potential return of 1408.62% based on the average OKUR price forecast.
Analyzing the OKUR fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.69, Equity is -1.9 and Total Capital is -0.77. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that OnKure Therapeutics Inc [NASDAQ:OKUR] has a current ratio of 11.17. In addition, the Quick Ratio stands at 11.17 and the Cash Ratio stands at 11.0.
Transactions by insiders
Recent insider trading involved Cormorant Asset Management, LP, Former 10% Owner, that happened on May 15 ’25 when 1.81 million shares were sold. 10% Owner, ACORN BIOVENTURES, L.P. completed a deal on May 15 ’25 to buy 1.13 million shares. Meanwhile, 10% Owner ACORN BIOVENTURES, L.P. bought 0.27 million shares on May 15 ’25.
